Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Classical hematology 3

Conditions

Leukemia, Myeloid, Acute 213Myelodysplastic Syndromes 82Leukemia 44Leukemia, Myelomonocytic, Chronic 35Recurrence 16Myeloproliferative Disorders 15Neoplasm, Residual 10Lymphoma, T-Cell, Peripheral 10Leukemia, Biphenotypic, Acute 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large B-Cell, Diffuse 7Anemia, Refractory, with Excess of Blasts 7Primary Myelofibrosis 6Lymphoma, Non-Hodgkin 6Hodgkin Disease 6Congenital Abnormalities 6Lymphoma, T-Cell 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Monocytic, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Polycythemia Vera 4Pancreatic Neoplasms 4Multiple Myeloma 4Lymphoma, Follicular 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Myeloid 4

Interventions

Cyclophosphamide 27fludarabine phosphate 21Cyclosporine 19Mycophenolic Acid 16Busulfan 16Cord Blood Stem Cell Transplantation 15Antilymphocyte Serum 14Whole-Body Irradiation 13Radiotherapy 13Peripheral Blood Stem Cell Transplantation 11Methylprednisolone 9Filgrastim 7Methotrexate 6Melphalan 6Tacrolimus 5fludarabine 4Thiotepa 4Etoposide 4Cytarabine 4sargramostim 3Granulocyte Colony-Stimulating Factor 3Cyclosporins 3Azacitidine 3Decitabine 2Arsenic Trioxide 24-phenylbutyric acid 2vatalanib 1poly ICLC 1paricalcitol 1lintuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Anemia, Refractory × Azacitidine × Clear all
NCT00234000 2020-07-31

Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Jonsson Comprehensive Cancer Center

Phase 1 Terminated
1 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00004871 2010-03-10

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡